ChiCTR2100049315
正在进行
/
/
/
2021-07-30
/
/
Borderline Personality Disorder; Pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.)
DBT in Hong Kong Mental Health Community Setting
The Effectiveness of Dialectical Behavior Therapy in a Mental Health Community Setting in Hong Kong
Dialectical Behavior Therapy (DBT) is an evidence-based treatment for individuals with symptoms of different psychiatric diagnoses (e.g., Cristea et al., 2017), particular those at risks for suicide or parasuicidal behavior (e.g., DeCou et al., 2019; Stanley et al., 2007) and those reporting emotion dysregulation (e.g., Kells et al., 2020). A transdiagnostic treatment that meets the needs of clinical populations at various risk levels can potentially mitigate the associated high cost to the health system as a whole. Considering the various components of DBT, establishment of a standard DBT program can be a multi-phasic project. Stand-alone DBT skills training groups have been found effective in reducing symptoms of mental health disorders (Valentine et al., 2014) and strengthening emotion regulation (Kells et al., 2020). Therefore, this study serves as a pilot and focuses on the effectiveness of skills training groups. Preliminary data collected will not only inform the projects subsequent phase(s) of expansion into a standard DBT program but also shed light on the implementation of DBT in an outpatient community setting in Hong Kong.
单臂
Ⅲ期
N/A
N/A
Lump sum grant
/
50
/
2021-07-14
2026-03-31
/
- Aged 18 years or up; - Speak, read, and write Chinese; - Meet diagnostic criteria of Borderline Personality Disorder; OR show traits of pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.); - Present treatment needs related to Stage 1 treatment targets as defined in DBT, such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Show elevation on screening measures such as the Borderline Symptom List 23 (BSL-23).;
请登录查看- Present with active psychosis without insight; - Demonstrate sub-average intelligence; - Decline to commit on Stage 1 treatment targets; that is, targets related to areas such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Concurrently receive other psychological services.;
请登录查看新生活精神康復協會
/
新生活精神康復協會的其他临床试验
香港新生活精神康復協會的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

